Maxim raised the firm’s price target on INmune Bio (INMB) to $30 from $22 and keeps a Buy rating on the shares. The company’s announcement related to positive data for a stem cell-based therap ...

Scotiabank raised the firm’s price target on INmune Bio (INMB) to $23 from $22 and keeps an Outperform rating on the shares. The company’s management appears confident a Biologics License ...

BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK ...

“The INmune Bio study represents a new immune therapy approach to treating advanced prostate cancer. The study involves the use of cellular therapy treatment that activates NK cells, which are ...

BOCA RATON, FLORIDA - INmune Bio , Inc. (NASDAQ: NASDAQ:INMB), a clinical-stage biotechnology company with a market capitalization of $212.74 million, announced today its plans to submit ...

Medical review of Phase 1 cohorts demonstrated no safety issues Data to be presented at the 10 th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE ...

Medical review of Phase 1 cohorts demonstrated no safety issues Data to be presented at the 10 th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio ...

Feb. 18, 2025 — The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study ...

Your immune system includes your body's cells, tissues, and organs, which work together to fight off infections and diseases. But how much do you know about it? When you understand everything that ...

INmune Bio's CEO, RJ Tesi MD, highlighted the VA Health Care System as an ideal setting for conducting clinical trials due to its high-quality care and diverse patient population. While the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...